BioNTech SE (BNTX) Announces 5M Share Proposed Public Offerings of ADSs and Rights Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
BioNTech Announces Proposed Public Offerings
July 21, 2020 8:50 AM EDTMAINZ, Germany, July 21, 2020 (GLOBE NEWSWIRE) -- BioNTech SEÂ (Nasdaq: BNTX, BioNTech or the Company) announced today the proposed public offerings described below. The completion of the proposed public offerings is subject to market and other factors.
BioNTech announced the commencement of a firm commitment underwritten offering (the Underwritten Offering) of 5,000,000 American Depositary Shares (ADSs), each representing one of its ordinary shares. In connection with the Underwritten Offering, an... MorePfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
July 20, 2020 8:45 AM EDTThe data further demonstrated the ability of BNT162b1 to elicit high SARS-CoV-2 neutralizing titersBNT162b1 elicited strong CD4+ and CD8+ T cell responses against SARS-CoV-2- receptor binding domain (RBD), compared to baselineThe RBD-specific, interferon-g+, IL-2+, CD8+ T cells elicited by BNT162b1 in immunized participants indicate a strong potential for cell mediated anti-viral activityT cell cytokine profile shows vaccine elicited T cells exhibit a Th1 phenotype, which is... More
